A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
The Evidence behind Inhibitor Treatment with Porcine Factor VIII
Pathophysiology of Haemostasis and Thrombosis
Factor VIII auto-and alloantibodies neutralise porcine factor VIII to a lesser extent than factor VIII of human origin. The reduced reactivity of the porcine molecule, predominantly due to sequence variation in the A2 and C2 domains, has been the rationale for using porcine factor VIII to secure haemostasis for patients with factor VIII inhibitors. Porcine factor VIII has been shown to provide effective haemostatic control particularly for patients with intermediate inhibitor titres withdoi:10.1159/000057292 pmid:12214138 fatcat:ota5ehfrc5gbdk7zcerslzcjei